Form 4: Ionis Pharmaceuticals Director Michael J. Yang Receives Stock Options

Director Michael J. Yang received stock options for 10,111 shares of Ionis Pharmaceuticals common stock on July 1, 2024, as part of the company's Non-Employee Director Compensation Policy.

Summary

• Michael J. Yang, a director at Ionis Pharmaceuticals, received a grant of non-qualified stock options on July 1, 2024.
• The options are for 10,111 shares of Ionis Pharmaceuticals common stock.
• The exercise price of the options is $47.11 per share.
• The grant was adjusted downward to ensure that the director's annual equity compensation in 2024 does not exceed $450,000, based on the aggregate grant date fair value.
• The options vest and become exercisable on the earlier of July 1, 2025, or the next regularly scheduled annual meeting of stockholders.
• The options expire on June 30, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options to a director, which is generally viewed as a positive sign of aligning management interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders and incentivizing them to increase company value.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the pharmaceutical industry depending on company size, performance, and board responsibilities.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation plans.
• The $450,000 equity compensation cap appears to be within a reasonable range for a director at a company of Ionis Pharmaceuticals' size and market capitalization.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to contribute to the company's success.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant.

Key Dates